Talphera Shares Soar 36% on Niyad's FDA Breakthrough Device Nod

Introduction to Talphera Inc

Talphera Inc (NASDAQ: TLPH) is trading at USD 0.5885 per share as of August 19, 2025, reflecting a one-day increase of 36.07%. The company’s trading volume reached 22,627,704 shares on the NASDAQ exchange. Talphera specializes in developing and commercializing therapies for use in medically supervised settings, focusing on innovative anticoagulant and pre-filled syringe products.

Corporate Structure

Founded in 2005 and headquartered in San Mateo, California, Talphera operates as a public company in the pharmaceutical manufacturing and research & development industry. According to LinkedIn data, the company employs between 51 and 200 professionals. Talphera transitioned from its former identity, AcelRx Pharmaceuticals, to its current name on January 10, 2024, which reflects a strategic mission extending beyond acute pain treatments to products for medically supervised care.

Pharmaceutical Innovation by Arthur Mazi

Recent Developments and News

On January 9, 2024, the company announced its rebranding to Talphera, effective January 10 on the NASDAQ Global Market under the ticker symbol TLPH. The lead product candidate, Niyad™ (nafamostat mesylate), received FDA Breakthrough Device designation. Top-line data from the ongoing clinical study of Niyad in continuous renal replacement therapy (CRRT) are expected by mid-2024. Talphera plans to submit a Premarket Approval (PMA) application for Niyad in the second half of 2024, following the initiation of the NEPHRO CRRT registrational study in the first quarter of 2024. The pipeline also includes LTX-608™ (anticipated to enter phase 3 post-toxicology) and two pre-filled syringes—Fedsyra™ (ephedrine) and PFS-02 (phenylephrine)—developed in partnership with Aguettant.

Financial and Strategic Analysis

Talphera’s most recent Form 10-Q, filed on August 14, 2025, covers the quarter ended June 30, 2025. While specific revenue and profitability figures are disclosed in that filing, key strategic drivers include the advancement of Niyad through clinical and regulatory milestones and diversification into pre-filled syringe products. The transition from an acute pain focus to a broader portfolio in medically supervised settings aligns with management's goal of optimizing patient care tools and expanding addressable markets.

Market Position and Industry Context

Within the extracorporeal circuit anticoagulation market, heparin has been the longstanding standard despite its associated bleeding risks in vulnerable patients. Niyad’s ultrashort half-life (eight minutes) and regional anticoagulation profile position it to address a gap for patients intolerant to heparin. Currently, there are no FDA-approved regional anticoagulants for dialysis circuits. Additionally, Talphera’s entry into ready-to-use pre-filled syringes targets hospital supply needs for vasopressors, potentially offering convenience and cost benefits to healthcare providers.

TL;DR

Talphera shares increased 36.07% to USD 0.5885 on August 19, 2025, amid progress toward mid-2024 top-line data for Niyad in CRRT and an anticipated PMA submission in the second half of 2024. The NEPHRO CRRT registrational study began patient enrollment in Q1 2024. Upcoming developments include clinical readouts, regulatory filings, and advancement of pre-filled syringe candidates in phase 3 development.